-
公开(公告)号：US20220251194A1
公开(公告)日：2022-08-11
申请号：US17630586
申请日：2020-07-28
摘要： Provided herein are treatments of conditions ameliorated by counteracting tumor mediated immune suppression. More specifically, provided herein are anti-PD-1/LAG-3/TIGIT trispecific antibodies, anti-PD-1/LAG3 bispecific antibodies, anti-LAG3 antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
-
公开(公告)号：US11052065B2
公开(公告)日：2021-07-06
申请号：US16649756
申请日：2018-09-24
发明人： Elaine M Pinheiro , Michael Rosenzweig , Robert A. Kastelein , David R. Kaufman , Deborah A. Law
IPC分类号： A61K31/341 , C07K16/28 , A61P35/04 , A61K39/00
摘要： The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
-
公开(公告)号：US20130287775A1
公开(公告)日：2013-10-31
申请号：US13925525
申请日：2013-06-24
发明人： Edward P. Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy L. Miller , Melanie A. Kleinschek , Kristian S. Bak-Jensen , Katia Boniface , Brent S. McKenzie , Rene de Waal Malefyt
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K31/55 , A61K31/5575 , A61K38/1793 , A61K39/395 , A61K45/06 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。
-
公开(公告)号：US20200276153A1
公开(公告)日：2020-09-03
申请号：US16649756
申请日：2018-09-24
发明人： Elaine M Pinheiro , Michael Rosenzweig , Robert A. Kastelein , David R. Kaufman , Deborah A. Law
IPC分类号： A61K31/341 , C07K16/28 , A61P35/04
摘要： The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
-
公开(公告)号：US20190338025A1
公开(公告)日：2019-11-07
申请号：US16415530
申请日：2019-05-17
发明人： Edward Bowman , Maribal Beaumont , Marie-Ange Buyse , Carlo Boutton , Bruno Dombrecht , Robert A. Kastelein , David Vlerick
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395 , C07K16/46 , C07K16/18
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
-
6.发明申请USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE 审中-公开使用IL-23和IL-17抗体治疗自身免疫性眼炎性炎症公开(公告)号：US20140248279A1
公开(公告)日：2014-09-04
申请号：US14274905
申请日：2014-05-12
申请人： Merck Sharp & Dohme Corp. , The Government of the United States of America as represented by the Secretary of the Department of
发明人： Daniel J. Cua , Robert A. Kastelein , Van T. Tsai , Rachel Caspi , Phyllis Silver , Dror Luger
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/76
摘要： Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
摘要翻译： 公开了用于治疗自身免疫性眼部炎性疾病的新方法和药物产品，其包括施用拮抗IL-17和IL-23活性中的一种或两种的药剂。
-
公开(公告)号：US08795666B2
公开(公告)日：2014-08-05
申请号：US13762133
申请日：2013-02-07
IPC分类号： A61K39/00 , A61K39/395 , C07K16/00
CPC分类号： A61K38/20 , A61K31/7088 , A61K38/1793 , A61K48/00 , C07K14/54 , C07K14/715 , C07K14/7155 , C07K16/244 , C07K16/2866 , C07K2319/00 , C12N15/1136 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12Q1/6876 , G01N33/6869 , G01N33/6893
摘要： Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
摘要翻译： 编码哺乳动物，例如灵长类动物，受体，纯化受体蛋白及其片段的核酸。 还提供了抗体，包括多克隆和单克隆抗体。 描述了用于诊断和治疗用途的组合物的方法。
-
8.发明申请公开(公告)号：US20140093875A1
公开(公告)日：2014-04-03
申请号：US14094511
申请日：2013-12-02
发明人： Pedro A. Reche-Gallardo , Vassili Soumelis , Yong-Jun Liu , Rene de Waal Malefyt , J. Fernando Bazan , Robert A. Kastelein
IPC分类号： C07K16/24 , G01N33/68 , C07K14/715
CPC分类号： C07K16/244 , C07K14/54 , C07K14/7155 , G01N33/6863 , G01N33/6869 , G01N2333/54 , G01N2500/02
摘要： Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
摘要翻译： 编码哺乳动物细胞因子受体的核酸，例如细胞因子IL-B50，纯化的蛋白质及其片段。 还提供了抗体，包括多克隆和单克隆抗体。 描述了用于诊断和治疗用途的组合物的方法。
-
公开(公告)号：US11168136B2
公开(公告)日：2021-11-09
申请号：US16415496
申请日：2019-05-17
发明人： Edward Bowman , Maribel Beaumont , Marie-Ange Buyse , Carlo Boutton , Bruno Dombrecht , Robert A. Kastelein , David Vlerick
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , A61K45/06 , C07K16/46
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
-
公开(公告)号：US11168135B2
公开(公告)日：2021-11-09
申请号：US16415455
申请日：2019-05-17
发明人： Edward Bowman , Maribel Beaumont , Marie-Ange Buyse , Carlo Boutton , Bruno Dombrecht , Robert A. Kastelein , David Vlerick
IPC分类号： C07K16/28 , C07K16/18 , A61K39/395 , A61K45/06 , C07K16/46
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.036 秒)
